PhaseV Partners with Crohn's & Colitis Foundation to Innovate IBD Research Through AI Technology

PhaseV and Crohn's & Colitis Foundation Unite for IBD Research

In a groundbreaking move for inflammatory bowel disease (IBD) research, PhaseV, a leader in artificial intelligence and machine learning (AI/ML) driven clinical development, has announced a strategic partnership with the Crohn's & Colitis Foundation. This collaboration aims to leverage the Foundation's renowned IBD Plexus® research accelerator, which houses a vast collection of IBD patient data and biosamples, to tackle critical challenges in the development of personalized therapies. Approximately 1 in 100 Americans suffer from IBD, making this partnership a significant step toward improved patient outcomes.

Angela Dobes, Senior Vice President of IBD Plexus at the Crohn's & Colitis Foundation, expressed the organization’s commitment to breaking barriers in clinical development. By combining the extensive patient data and biosamples provided by IBD Plexus with PhaseV's advanced AI/ML solutions, they aim to design more flexible and patient-centric trials. This approach emphasizes the importance of real-time adaptation in study designs, thereby enhancing the probability of success in clinical trials for IBD therapies.

Traditionally, designing effective trials for IBD treatments has been complex due to the heterogeneity in disease presentation, progression, and patient responses to treatment. Factors such as disease subtype, location, severity, and genetic background contribute to this challenge, often leading to substantial variations in outcomes from trial results. The reliance on predefined assumptions and static trial designs frequently results in high failure rates and prolonged timelines for treatment approval.

The partnership between PhaseV and the Crohn's & Colitis Foundation promises to bridge these gaps by employing a data-driven approach to clinical trials. By integrating the Foundation's rich dataset with PhaseV's innovative AI technology, clinical teams will be able to gain insights from accumulating data and adjust trial designs on-the-fly. This adaptability is essential for addressing the diverse needs of IBD patients and enhancing the efficiency of the clinical development process. Furthermore, PhaseV's causal disease modeling capabilities can help sponsors identify significant biomarker-outcome relationships, thereby providing deeper insights into IBD.

Dr. Raviv Pryluk, CEO and Co-founder of PhaseV, highlighted the complexity of IBD and the necessity for innovative research methodologies. He articulated the commitment of both organizations to tackle pressing challenges in developing IBD therapies, ultimately aiming to expedite the delivery of effective treatments for patients struggling with this condition.

About PhaseV
PhaseV specializes in developing advanced AI/ML solutions that optimize clinical development. Their platform assists biopharma sponsors and contract research organizations (CROs) by facilitating the rapid design and execution of adaptive, Bayesian, and traditional clinical trials. Additionally, PhaseV's platform, enriched with a comprehensive data lake that includes patient-level data and real-world evidence, has demonstrated the ability to reduce trial costs by 50%, cut enrollment sizes and durations by 40%, and increase the likelihood of trial success by over 30%. Since its inception, PhaseV has produced results for more than 30 leading pharma/biotech sponsors and CROs across various therapeutic areas, including oncology and immunology.

About the Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is a leading nonprofit organization dedicated to supporting research and patient care for IBD. Their mission is to find cures for Crohn's disease and ulcerative colitis while enhancing the quality of life for the millions in America living with IBD. The Foundation accelerates research processes and provides extensive educational resources for patients, medical professionals, and the public. This partnership with PhaseV is expected to further this mission effectively, driving progress towards more effective treatments and improved patient outcomes.

Together, PhaseV and the Crohn's & Colitis Foundation are set to innovate IBD research and therapy development, empowering patients with the hope of more personalized and effective treatments.